Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Drug metabolism in human hepatocytes assessed as formation of FMO-mediated N,N-Dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Genome-wide siRNA screen of genes regulating the Lipopolysaccharide-induced TNF-alpha response in human macrophages_Primary screen TNF readout
Assay data:2853 Active, 18113 Tested
SummaryRelated BioAssays by Same Project
Drug metabolism assessed as human recombinant FMO5-mediated ER-879123 formation in absence of human liver cytosolic fractions at 50 uM after 60 mins by LC-MS/MS method
Drug metabolism assessed as human recombinant FMO5-mediated ER-879123 formation in absence of dog liver cytosolic fractions at 50 uM after 60 mins by LC-MS/MS method
Drug metabolism assessed as human recombinant FMO5-mediated ER-879123 formation in absence of rat liver cytosolic fractions at 50 uM after 60 mins by LC-MS/MS method
Drug metabolism assessed as human recombinant FMO5-mediated compound formation from 50 uM E7016 in presence of dog liver cytosolic fractions after 60 mins by LC-MS/MS method
Drug metabolism assessed as human recombinant FMO5-mediated compound formation from 50 uM E7016 in presence of human liver cytosolic fractions after 60 mins by LC-MS/MS method
Drug metabolism assessed as human recombinant FMO5-mediated compound formation from 50 uM E7016 in presence of rat liver cytosolic fractions after 60 mins by LC-MS/MS method
Drug metabolism assessed as human recombinant FMO5-mediated ER-879123 formation in presence of human liver cytosolic fractions at 50 uM after 60 mins by LC-MS/MS method
Drug metabolism assessed as human recombinant FMO5-mediated ER-879123 formation in presence of dog liver cytosolic fractions at 50 uM after 60 mins by LC-MS/MS method
Drug metabolism assessed as human recombinant FMO5-mediated ER-879123 formation in presence of rat liver cytosolic fractions at 50 uM after 60 mins by LC-MS/MS method
Drug level assessed as human recombinant FMO5-mediated compound formation from 10 uM ER-879819 in presence NADH after 60 mins by LC-MS/MS method
Drug level assessed as human recombinant FMO5-mediated compound formation from 10 uM ER-879819 in presence NADPH after 60 mins by LC-MS/MS method
Drug metabolism assessed as human recombinant FMO5-mediated ER-879123 formation in presence NADH at 10 uM after 60 mins by LC-MS/MS method
Drug metabolism assessed as human recombinant FMO5-mediated ER-879123 formation at 10 uM after 60 mins by LC-MS/MS method in presence of NADPH
A screen to identify synthetic lethal interactions with E-cadherin in an MCF10A isogenic cell line
Assay data:2442 Active, 18052 Tested
SummaryPubMed Citation
A screen to identify genes that regulate lymphatic endothelial cell migration - Primary Screen
Assay data:1034 Active, 18120 Tested
SummaryRelated BioAssays by Depositor
Identification of proteins required for the processing of the EWS-FLI1 nascent transcript
Assay data:59220 Tested
InfectX: Pathogen infection siRNA screens
Assay data:115372 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on